|1.||Neurath, A Robert: 3 articles (05/2006 - 05/2005)|
|2.||Jiang, S: 2 articles (10/2010 - 01/2005)|
|3.||Liu, Shuwen: 2 articles (05/2006 - 05/2005)|
|4.||Lu, Hong: 2 articles (05/2006 - 05/2005)|
|5.||McCormack, S: 1 article (10/2010)|
|6.||Woodhall, S: 1 article (10/2010)|
|7.||Qi, Z: 1 article (10/2010)|
|8.||Sawant, S: 1 article (10/2010)|
|9.||Cowen, M: 1 article (10/2010)|
|10.||Lacey, C J: 1 article (10/2010)|
05/01/2006 - "Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates."
10/14/2005 - "To evaluate the protective efficacy of cellulose acetate 1,2-benzenedicarboxylate (CAP) formulated in a glycerol-based gel against infection with CXCR4 (X4) and CCR5 (R5) viruses in the simian/human immunodeficiency virus (SHIV)/rhesus macaque model of HIV-1 transmission. "
05/01/2006 - "Cellulose acetate 1,2-benzenedicarboxylate (CAP), a pharmaceutical excipient used for enteric film coating of capsules and tablets, was previously shown to have potent inhibitory activity against infection by human immunodeficiency virus type 1 (HIV-1) T cell line-adapted (TCLA) strains. "
05/01/2005 - "Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection."
05/01/2005 - "The combination of two candidate microbicides, cellulose acetate 1,2-benzenedicarboxylate (CAP), a polymer that blocks human immunodeficiency virus type 1 (HIV-1) entry by targeting gp120 and gp41, and UC781, a tight-binding HIV-1 reverse transcriptase inhibitor (RTI), resulted in effective synergy for inhibition of MT-2 cell infection by HIV-1(IIIB), a laboratory-adapted virus strain. "
|2.||Sexually Transmitted Diseases (Sexually Transmitted Disease)
|4.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/2005 - "Cellulose acetate 1,2-benzenedicarboxylate, also named CAP (for "controls AIDS pandemic"), is an anti-HIV-1 microbicide selected from pharmaceutical excipients that are regarded as safe for oral administration but have not been assessed for potential effects on inflammatory factors in the vaginal environment. "
|2.||cellulose acetate phthalate
|5.||Excipients (Suspending Agents)
|6.||Anti-Infective Agents (Microbicides)
|7.||Human immunodeficiency virus 1 reverse transcriptase